10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Localised anal cancer is squamous cell cancer of the anal canal that has not spread beyond the pelvis and groin, one of the few cancers cured mainly by chemotherapy and radiotherapy together rather than by surgery. Fluorouracil with mitomycin during radiotherapy is the standard, confirmed by the ACT II trial; surgery to remove the anus is kept for the minority whose cancer persists or returns.
Anal squamous cell carcinoma confined to the anal canal, the pelvic nodes and the groin nodes is treated to keep the anus. Before 1974 the standard was abdominoperineal resection with a permanent colostomy; Norman Nigro then showed that fluorouracil and mitomycin given during radiotherapy made most tumours disappear, and the UKCCCR ACT I and EORTC trials in the 1990s proved chemoradiotherapy beat radiotherapy alone. ACT II (Lancet Oncology 2013), with 940 patients the largest anal cancer trial when it reported, found that cisplatin was no better than mitomycin alongside fluorouracil and radiotherapy (complete response at 26 weeks in 89.6 against 90.5 percent) and that maintenance chemotherapy added nothing. A later analysis of the same trial (Lancet Oncology 2017) showed that tumours keep regressing for months: of patients assessed at all three time points who were not in complete response at 11 weeks, 72 percent had reached it by 26 weeks, so response should be judged at 26 weeks before anyone is sent for surgery. In RTOG 98-11, cisplatin given first and then with radiotherapy did no better than mitomycin: the first report (2008) found more colostomies with cisplatin and no significant difference in disease-free survival, and the long-term update (2012) found disease-free and overall survival significantly better with mitomycin.
Today's treatment is intensity-modulated radiotherapy with concurrent fluorouracil (or capecitabine) and mitomycin, with the dose scaled to stage; very small well-differentiated perianal tumours can be excised alone. Salvage abdominoperineal resection is offered when biopsy confirms persistent or recurrent disease. HPV or p16 status is favourable and HIV is no longer a bar to full-dose treatment when CD4 counts are adequate. The UK PLATO programme (ACT3, ACT4 and ACT5), which recruited 709 patients between 2017 and 2023, tests lower doses for early tumours and higher doses for locally advanced ones; ACT4 has reported complete responses six months after treatment in 92 percent of patients given the reduced dose and 87 percent given the standard dose (Lancet Oncology 2025), with its primary three-year results still to come. EA2165, which tests nivolumab after chemoradiotherapy for high-risk disease, has closed to recruitment and not yet reported, and circulating HPV DNA is being studied as a way to tell early who is cured.
| Setting | Approach | Guideline |
|---|---|---|
| Staging | Pelvic MRI, PET-CT, examination of the groins, HIV testing and HPV or p16 status; biopsy of suspicious groin nodes. | not mapped |
| Stage I to III | Intensity-modulated radiotherapy with concurrent fluorouracil (or capecitabine) and mitomycin, dose scaled to stage (ACT II, RTOG 98-11); small perianal tumours may be excised alone. | not mapped |
| Response assessment | Clinical assessment at 26 weeks; biopsy only if disease persists or grows, because regression continues for months (ACT II). | not mapped |
| Persistent or recurrent disease | Salvage abdominoperineal resection with permanent colostomy; inguinal node dissection or radiotherapy for isolated groin recurrence. | not mapped |
| High-risk locally advanced disease | Dose escalation (PLATO ACT5) and adjuvant nivolumab (EA2165) are being tested in trials that have finished recruiting and not yet reported their main results; standard care remains chemoradiotherapy alone. | not mapped |